AbbVie & Genmab EHA Data Indicate LBCL Drug Could Fill Unmet Need

Danish biotechnology company Genmab A/S and Chicago biotech behemoth AbbVie announced primary results from the Phase II expansion cohort of their EPCORE NHL-1 clinical trial. The data revealed that the investigational bispecific antibody, epcoritamab, induced a deep and durable response in patients with large B-cell lymphoma (LBCL).